AZUSA, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. will exhibit at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco from September 27 to 30, 2006. This is the first year Viral Genetics, booth #1728, will be exhibiting at the conference.
Viral Genetics is currently developing VGV-1, a thymus nuclear protein therapy for the treatment of HIV/AIDS. In a recent Phase III trial in South Africa, statistically significant reductions in viral load were seen in 22% of patients that were equivalent to a 70% decrease in the amount of virus in the blood at day 150 (approximately three months after treatment).
The conference is sponsored by the American Society for Microbiology and will be held at the Moscone Center in San Francisco, California. The conference expects more than 12,000 physicians, researchers, and healthcare professionals will attend to discuss and foster solutions to infectious diseases. Additional conference information is available online at www.icaac.org.
About VGV-1
VGV-1 is a therapy based on thymus nuclear protein which is extracted from bovine thymus tissue. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. Discovered and developed by both Drs. Harry Zhabilov Sr. and Jr., thymus nuclear protein technology has been studied in five human clinical trials for the treatment of HIV infection and AIDS.
About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies using its thymus nuclear protein compound for HIV and AIDS along with other infectious, autoimmune, and immunological deficiency diseases. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com
For additional information, please contact Kirsten Ayars at 805-452-7909. For investor inquiries, please contact Evan Pondel at 310-279-5973.
This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition and the development of studies and strategies leading to commercialization of VGV-1 in the United States. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
Viral Genetics, Inc.
CONTACT: Kirsten Ayars, +1-805-452-7909, or investors, Evan Pondel,+1-310-279-5973, both for Viral Genetics, Inc.
Company News On-Call: http://www.prnewswire.com/comp/905553.html
